Skip to Main Content
Table 2

Patient characteristics

n%
No. with measurable disease 16 94 
No. with nonmeasurable disease 
Age   
 Median 58  
 Range 39–73  
Histology   
 Papillary serous 13 76 
 Other 24 
Initial tumor grade   
 1 
 2 12 
 3 14 82 
Performance status   
 0 10 59 
 1 41 
No. of prior chemotherapy regimens   
 Median  
 Range (1–5)  
Response to first chemotherapy regimen   
 CR 11 65 
 PR 24 
 No response/progression 
 Unknown 
Platinum sensitivity   
 Sensitive 47 
 Resistant 53 
Taxane sensitivity   
 Sensitive 47 
 Resistant 53 
Time since last platinum (mo)   
 Median 41 
 Range (1–19)  
Time since last paclitaxel (mo)   
 Median 41 
 Range (1–27)  
n%
No. with measurable disease 16 94 
No. with nonmeasurable disease 
Age   
 Median 58  
 Range 39–73  
Histology   
 Papillary serous 13 76 
 Other 24 
Initial tumor grade   
 1 
 2 12 
 3 14 82 
Performance status   
 0 10 59 
 1 41 
No. of prior chemotherapy regimens   
 Median  
 Range (1–5)  
Response to first chemotherapy regimen   
 CR 11 65 
 PR 24 
 No response/progression 
 Unknown 
Platinum sensitivity   
 Sensitive 47 
 Resistant 53 
Taxane sensitivity   
 Sensitive 47 
 Resistant 53 
Time since last platinum (mo)   
 Median 41 
 Range (1–19)  
Time since last paclitaxel (mo)   
 Median 41 
 Range (1–27)  
Close Modal

or Create an Account

Close Modal
Close Modal